Skip to main content Accessibility help
×
Hostname: page-component-7b7567c8c-2n9c9 Total loading time: 0 Render date: 2026-11-17T04:53:19.626Z Has data issue: false hasContentIssue false

9 - Bayesian inference for model selection: an application to aberrant signalling pathways in chronic myeloid leukaemia

Published online by Cambridge University Press:  05 July 2015

Lisa E. M. Hopcroft
Affiliation:
University of Glasgow
Ben Calderhead
Affiliation:
University College London
Paolo Gallipoli
Affiliation:
University of Glasgow
Tessa L. Holyoake
Affiliation:
University of Glasgow
Mark A. Girolami
Affiliation:
University College London
Florian Markowetz
Affiliation:
Cancer Research UK Cambridge Institute
Michael Boutros
Affiliation:
German Cancer Research Center, Heidelberg
Get access

Summary

In the analysis of any data using statistical modelling, it is imperative that the choice of model is informed by expert knowledge and that its adequacy is determined based on the extent to which it captures and describes the patterns observed in the data. This is especially true in systems where a subset of the constituent components may not be known or cannot be observed. In this chapter, we demonstrate how statistical inference can be used to inform model selection and, by identifying where existing models are unable to sufficiently capture observed behaviour, that statistical inference can help indicate which model refinements may be required.

In this chapter, we use Bayesian statistical methodology – specifically, Riemannian manifold population MCMC – to model interactions between molecular species in the JAK/STAT pathway in chronic myeloid leukaemia (CML) and compare two candidate models. We set out the biological context for this inference in Sections 9.1–9.1.4 and describe the two candidate models in Section 9.3. With the biology established, we describe our statistical methodology (Section 9.4) which we successfully apply in a simulation study to provide a proof of concept (Section 9.5), before we consider a subsequent, more biologically realistic dataset (Section 9.6) to assess which model best describes the behaviour observed in vitro. We relate the findings from this second synthetic study back to our model and dataset construction, thereby highlighting what further in vitro and in silico work is required (Section 9.7).

The oncology of chronic myeloid leukaemia

The condition that we now recognise as chronic myeloid leukaemia (CML) was first described in 1845, in quick succession, by two pathologists, Dr John Hughes Bennett (Bennett 1845) and Dr Rudolf Virchow (Virchow 1845).

Information

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×